tbuckley/cabot-search huggingface dataset:
Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma
Authors: Lora Hamuro, Zheyi Hu, Julie Passarell, Heather Barcomb, Joshua Zhang, Shay Goldstein, Akintunde Bello, Amit Roy, Li Zhu
Journal: Clinical Cancer Research (2022)

Abstract Purpose: A benefit:risk assessment for a less-frequent nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day dosing regimen was predicted using modeling and simulation of clinical trial data from nivolumab monotherapy studies and from the nivolumab 240 mg every 2 weeks + cabozantinib 40 mg every day dosing regimen, which demonstrated clinical benefit versus sunitinib in previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 9ER trial (NCT03141177). Patients and Methods: Multivariable Cox proportional hazards analyses were conducted using nivolumab monotherapy data in previously treated aRCC and data from CheckMate 9ER to evaluate progression-free survival (PFS), overall survival (OS), and grade ≥2 immune-mediated adverse events (IMAE). Results: Nivolumab 240 mg every 2 weeks + cabozantinib versus nivolumab monotherapy showed improvement in PFS (HR, 0.38; 95% CI, 0.31–0.47), OS (HR, 0.63; 95% CI, 0.46–0.85), and increased risk of grade ≥2 IMAEs (HR, 2.19; 95% CI, 1.79–2.67). Nivolumab exposure was not a predictor of PFS/OS or grade ≥2 IMAEs. Lower nivolumab clearance, male sex, higher baseline bodyweight, and Karnofsky performance (100) were each associated with PFS/OS improvements. Region and International Metastatic Renal Cell Carcinoma Database Consortium poor score were negative OS predictors. Age, baseline albumin, and programmed death ligand 1 status were not significant PFS/OS predictors. Cabozantinib was a significant grade ≥2 IMAE predictor, driven by diarrhea and hepatic events. Model-predicted PFS/OS and grade ≥2 IMAE rates were similar (&amp;lt;2.5% difference) for nivolumab 240 mg every 2 weeks + cabozantinib and 480 mg every 4 weeks + cabozantinib. Conclusions: Comparable benefit:risk was predicted for nivolumab 480 mg every 4 weeks + cabozantinib and nivolumab 240 mg every 2 weeks + cabozantinib.
Relational mentalizing after any representation
Authors: Eliane Deschrijver
Journal: Behavioral and Brain Sciences (2021)

Abstract Autistic, developmental, and nonhuman primate populations fail tasks that are thought to involve attributing beliefs, but not those thought to reflect the representation of knowledge. Instead of knowledge representations being more basic than belief representations, relational mentalizing may explain these observations: The tasks referred to as reflecting “belief” representation, but not the “knowledge” representation tasks, are social conflict designs. They involve mental conflict monitoring after another's mental state is represented – with effects that need to be accounted for.
The Cover
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PLoS Medicine Issue Image | Vol. 5(2) February 2008
Journal: PLoS Medicine (2008)

The cover image this month comes from a unique collaborative study that found evidence that fake antimalarial drugs are being manufactured in China, prompting a criminal investigation (Newton, et al. e32). The image is of a hologram copy of one of the fake artesunate drugs; in Figure 2 of the study, a fake hologram can be seen under UV light. Most of the fakes contained no artesunate. Many contained wrong active ingredients, including banned pharmaceuticals such as metamizole and the carcinogenic drug safrole. Some contained dangerously small amounts of artesunate: enough to foil screening tests, too low to treat malaria, yet high enough to encourage the spread of malaria parasites resistant to the medicine. The study involved the international police organization INTERPOL and led to the arrest of a gang in Yunnan, China, alleged to be responsible for producing almost half of the counterfeit artesunate in Southeast Asia. Surveillance of another kind is debated in this issue (Chandramohan, et al. e57): demographic surveillance, the process of monitoring birth, deaths, causes of deaths, and migration in a population over time. The proprietorial, managerial, and financial obstacles to the sharing of demographic surveillance data are discussed. As the editorial for the issue points out, PLoS ONE is one venue for making such data freely and publicly available. Image Credit: Figure 2C from Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, et al.
Baseline results of the heart failure practice improvement effort (HF PIE): A pilot Health Care Financing Administration (HCFA) initiative to improve out-patient care Neal D. Traven, Jane P. Taylor, Risa K. Hayes, Christine L. Mulgrew, Harlan M. Krumholz, Diana L. Ordin. Health Care Financing Administration, Boston, MA, Northeast Health Quality Foundation, Dover, NH
Journal: Journal of the American College of Cardiology (2001)
CHIROPRACTORS AND NATUROPATHS DEFEATED
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Re: Marc Sbizzera, Nicolas Morel-Journal, Alain Ruffion, et al. Rectourethral Fistula Induced by Localised Prostate Cancer Treatment: Surgical and Functional Outcomes of Transperineal Repair with Gracilis Muscle Flap Interposition. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.09.017
Authors: Jas Singh
Journal: European Urology (2022)
Safety and tolerability of combined niacin plus simvastatin in CAD patients with low HDLc with or without diabetes Xue-Qiao Zhao, B. Greg Brown, Josh S. Morse, Alice Dowdy, Debbie DeAngelis, Jiri Frohlich, Alan Chait, John J. Albers. University of Washington, Seattle, WA, University of British Columbia, Vancouver, BC, Canada
Journal: Journal of the American College of Cardiology (2001)
News &amp; Notes
Journal: Journal of Allergy and Clinical Immunology (2020)

We also continue to update our Ask the AAAAI about COVID-19 section with answers to your questions, and don't forget you can check the resource page for all our advocacy updates in regards to COVID-19.If you have questions about COVID-19, please email practicematters@aaaai.org.As this pandemic continues, make sure to take some time to take care of yourself, both physically and mentally.The AAAAI has created a Physician Wellness and Resilience section filled with tips and information to help you.Read published papers from AAAAI journals, watch videos and review short articles on a variety of topics related to wellness.Once again, you can find a link to our COVID-19 resources page at education.aaaai.org.
Lack of association between genetic polymorphism of CYP11B2 gene and hypertension in Japanese: The Suita study Yasuyuki Tsujita, Shunroku Baba, Shinji Tamaki, Mashiko Kinoshita, Tomohiro Katsuya, Jitsuo Higaki, Toshio Ogihara, Toshifumi Mannami, Jun Ogata, Naoharu Iwai. Shiga University of Medical Science, Otsu, Japan, National Cardiovascular Center, Suita, Japan
Journal: Journal of the American College of Cardiology (2001)
Health education in rheumatology.
Authors: Lawren Daltroy, Matthew Liang, V Wright, P Helliwell
Journal: Annals of the Rheumatic Diseases (1991)

Facility to store and update searches * Facility to download-that is, capture infor- mation from the system onto the user's own disc for later use on their own personal computer to manage the references selected for quick retrieval and bibliography generation when writing.This is a major and crucially important develop- ment.been compared by Herman'9 with specific reference to downloading from MEDLINE or CD-ROM.
A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.
Authors: Debashis Sarker, Udai Banerji, Sarah Patricia Blagden, Natalie Cook, T.R. Jeffry Evans, Elizabeth Ruth Plummer, Marina Braun, Ann Cleverly, Nieves Diaz, Paul Jones, Ivan Matthews, Sophie Glatt
Journal: Journal of Clinical Oncology (2022)

TPS221 Background: Despite recent advances, effective treatment for GI cancers remains a significant unmet medical need. Gremlin-1 is secreted by the peri-tumoral stroma and down-regulates bone morphogenetic proteins (BMP) -2, -4, and -7 (members of the transforming growth factor-β superfamily), thereby allowing malignant cell expansion, renewal, and a more treatment-resistant mesenchymal phenotype. Gremlin-1 mRNA is highly expressed in multiple solid tumors including &gt;60% of colorectal, pancreatic and esophageal cancers. UCB6114 is a first-in-class, fully human IgG4P monoclonal antibody optimized for neutralizing the activity of human Gremlin-1 thereby restoring BMP signaling. Preclinical studies have demonstrated that UCB6114 binds to Gremlin-1, inhibits its pharmacological activity, and has antitumor activity in several in vivo mouse models (including several GI cancers). Methods: ONC001 (clinicaltrials.gov: NCT04393298) is an ongoing multi-part, multicenter, nonrandomized, open-label, Phase I/II study evaluating the safety, pharmacokinetics (PK) and antitumor activity of UCB6114 administered intravenously as monotherapy or in combination with selected standard of care (SOC) regimens. Eligible patients (pts) are: aged ≥18 years; resistant or refractory to standard therapy; ECOG performance status 0/1; and have adequate renal, hepatic and bone marrow function. In the Phase I monotherapy dose escalation and adaption part (part A and A1; modified rolling 6 design), up to 66 pts with advanced solid tumors associated with high levels of Gremlin-1 mRNA expression will be recruited. In parts B and C (modified toxicity probability interval design), up to 54 pts with locally advanced or metastatic colorectal, gastric or gastroesophageal junction adenocarcinomas will receive UCB6114 in escalating doses in combination with either mFOLFOX6 (5-fluorouracil, leucovorin and oxaliplatin) or trifluridine/tipiracil, given at SOC dosing and schedules. The overarching objective of the phase I parts of the study (Parts A‒C) is to identify the recommended phase II dose of UCB6114 either as monotherapy or in combination. The primary objective is to characterize the safety profile of UCB6114; secondary and exploratory objectives include PK, antitumor activity (RECIST v1.1), and pharmacodynamics (including circulating Gremlin-1). Enrollment in ONC001 began in July 2020; as of Sept 2021, four dose escalation levels in the monotherapy dose-escalation module (Part A) have been completed without DLT. Recruitment to parts B and C is due to commence in Q4 2021. Clinical trial information: NCT04393298.
Modulation of mucin and collagen ?1(IV) gene expression in human gallbladder epithelial cell primary cultures . Unit� de Recherches H�patologiques, INSERM U-49 and Clinique Chirurgicale, Facult� de M�decine, CHRU Pontchaillou, 35033 RENNES; *INSERM u-377, 59045 LILLE, France
Journal: Hepatology (1995)
Patient report outcomes: Financial toxicity in cholangiocarcinoma.
Authors: Jessica M. Keilson, Stacie Lindsey, Melinda Bachini, Caroline Medin, Alexandra Berk, Sophia Cornew, Shishir K. Maithel
Journal: Journal of Clinical Oncology (2022)

394 Background: While surgery is the only curative option for cholangiocarcinoma (CCA), it is amenable only in a minority of patients and has high recurrence rates. Numerous experimental and targeted therapies are under investigation; however, objective health-related quality of life (HRQoL) data for patients receiving these therapies are currently not available. Methods: Pts engaged in the Cholangiocarcinoma Foundation completed two validated HRQoL surveys: Functional Assessment of Cancer Therapy (FACT)-Hepatobiliary and COmprehensive Score for financial Toxicity (COST). Subscales (Physical Well-Being, PWB; Social Well-Being, SWB; Emotional Well-Being, EWB; Functional Well-Being, FWB; Hepatobiliary Cancer Subscale, HCS; Financial Toxicity Scale, FTS) and composite scores (FACT-Hep, composite for PWB, SWB, EWB, FWB, HCS) were calculated according to the FACIT-Manual, with higher values indicating improved HRQoL. Results: 208pts completed the surveys. 75% (n = 156) had intrahepatic CCA, 57% (n = 119) underwent resection, of which 48% (n = 56) had disease recurrence. 22% (n = 45) enrolled in a clinical trial and 80% (n = 167) underwent molecular profiling, of which 29% (n = 48) received targeted therapy. While pts enrolled in a clinical trial reported similar HRQoL compared to those not enrolled in a clinical trial, they also reported lower FTS (effect size 0.33, p = 0.05), suggesting higher financial burden. Pts who received targeted therapy reported equivalent HRQoL and lower FTS compared to those who did not (effect size 0.43, p = 0.01). Conclusions: Our data suggest that enrollment in a clinical trial does not affect a patient’s physical, emotional, social, or functional well-being. However, despite these treatments being paid for through trial enrollment, patients still report higher financial burden. This is also seen among patients who received targeted therapy. For patients with CCA, clinical trials and personalized therapy are mainly offered late in the advanced disease setting, at which point a significant financial toll has already been endured. Further, they are often only available at large academic centers, creating a physical barrier to access. These findings underscore the need to increase clinical trial availability and eliminate physical and financial barriers that threaten access and utilization of personalized and progressive therapies.[Table: see text]
Properties and Actions of Bridged Diphenyl Acaricides
Authors: Ralph B. March
Journal: Environmental Health Perspectives (1976)

The properties and actions of the bridged diphenyl acaricides are discussed. These pesticides, which are more or less structurally related to DDT, were the first of the specific acaricides to be developed. They exhibit remarkable properties of specificity, being primarily toxic to phytophagous mites but of very low toxicity to most nontarget species, including insects, fish, birds, and mammals. Although many important facets of their broad mode of action are understood, virtually nothing is known of their primary mode of action or the underlying bases of their specificities. In most ways they are model compounds for integrated control and pest management activities and thus merit greater attention than they have received to elucidate the fundamentals underlying their unusual properties and actions.
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups
Authors: Heiko Schöder, Thomas A. Hope, Michael Knopp, William K. Kelly, Jeff M. Michalski, Seth P. Lerner, Abdul Tawab-Amiri, Bhupinder S. Mann, Daniel W. Lin, Evan Y. Yu, Ronald C. Chen, Gillian C. Beach, Steven A. Reeves, Lalitha K. Shankar
Journal: Journal of Clinical Oncology (2022)

As prostate-specific membrane antigen (PSMA) positron emission tomography (PET) becomes increasingly available in the United States, the greater sensitivity of the technology in comparison to conventional imaging poses challenges for clinical trials. The NCI Clinical Imaging Steering Committee (CISC) PSMA PET Working Group was convened to coordinate the identification of these challenges in various clinical scenarios and to develop consensus recommendations on how best to integrate PSMA PET into ongoing and upcoming National Clinical Trials Network (NCTN) trials.NCI CISC and NCI Genitourinary Steering Committee members and leadership nominated clinicians, biostatisticians, patient advocates, and other imaging experts for inclusion in the PSMA PET Working Group. From April to July 2021, the working group met independently and in conjunction with the CISC to frame challenges, including stage migration, response assessment, trial logistics, and statistical challenges, and to discuss proposed solutions. An anonymous, open-ended survey was distributed to members to collect feedback on challenges faced. Representatives from each NCTN group were invited to present an overview of affected trials. From these discussions, the consensus document was developed and circulated for the inclusion of multiple rounds of feedback from both the Working Group and CISC.The current consensus document outlines the key challenges for clinical prostate cancer trials resulting from the increasing availability of PSMA PET. We discuss implications for patient selection and definition of end points and provide guidance and potential solutions for different clinical scenarios, particularly with regard to best practices in defining eligibility criteria and outcome measures.This article provides guidance regarding clinical trial design and conduct, and the interpretation of trial results.
Correction to Lancet Gastroenterol Hepatol 2020; published online June 8. https://doi.org/10.1016/S2468-1253(20)30185-0
Journal: The Lancet. Gastroenterology & hepatology (2020)

The title of this Comment should read "Faecal immunochemical testing in the COVID-19 era: balancing risk and costs" and the final sentence of the first paragraph should read "…including use of tests such as faecal immunochemical testing (FIT) for haemoglobin to diagnose colorectal cancer".Also in this Comment, Steve Smith's affiliation should have been, "Midlands and North West NHS England Bowel Cancer Screening Programme Hub", and minor corrections for clarity have been made to paragraph two, three, and the penultimate paragraph.These corrections have been made to the online version as of June 19, 2020, and the printed version is correct.
Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis
Authors: Hajra Khattak, Rosamund Malhas, Laurentiu Craciunas, Yousri Afifi, Christiani A Amorim, Simon Fishel, Sherman Silber, Debra Gook, Isabelle Demeestere, Olga Bystrova, Alla Lisyanskaya, Georgy Manikhas, Laura Lotz, Ralf Dittrich, Lotte Berdiin Colmorn, Kirsten Tryde Macklon, Ina Marie Dueholm Hjorth, Stine Gry Kristensen, Ioannis Gallos, Arri Coomarasamy
Journal: Human Reproduction Update (2022)

Ovarian tissue cryopreservation involves freezing and storing of surgically retrieved ovarian tissue in liquid or vapour nitrogen below -190°C. The tissue can be thawed and transplanted back with the aim of restoring fertility or ovarian endocrine function. The techniques for human ovarian tissue freezing and transplantation have evolved over the last 20 years, particularly in the context of fertility preservation in pre-pubertal cancer patients. Fresh ovarian tissue transplantation, using an autograft or donor tissue, is a more recent development; it has the potential to preserve fertility and hormonal function in women who have their ovaries removed for benign gynaecological conditions. The techniques of ovarian tissue cryopreservation and transplantation have progressed rapidly since inception; however, the evidence on the success of this intervention is largely based on case reports and case series.
Current Comment
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology
Authors: Wilfried Mullens, Andrew Coats, Petar Seferovic, Marco Metra, Alexandre Mebazaa, Frank Ruschitzka, Gerasimos Filippatos, Maurizio Volterrani, Piotr Ponikowski, Ewa A. Jankowska, Ovidiu Chioncel, Theresa A. McDonagh, Massimo F. Piepoli, Davor Milicic, Thomas Thum, Loreena Hill, Magdy Abdelhamid, Stamatis Adamopoulos, Yuri Belenkov, Tuvia Ben Gal, Michael Böhm, Alain Cohen‐Solal, Finn Gustafsson, Tiny Jaarsma, Brenda Moura, Amina Rakisheva, Arsen Ristic, Antonio Bayes‐Genis, Sophie Van Linthout, Stefan D. Anker, Carlo Gabriele Tocchetti, Yury Lopatin, Lars Lund, Gianluigi Savarese, Jelena Čelutkienė, Martin Cowie, Ekaterini Lambrinou, Robin Ray, Mitja Lainscak, Hadi Skouri, Markus Wallner, Giuseppe M.C. Rosano
Journal: European Journal of Heart Failure (2022)
Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)
Authors: Keith Pratz, Mohamad Cherry, Jessica K. Altman, Brenda W. Cooper, Jose Carlos Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci
Journal: Blood (2017)